Application de la biologie moléculaire à la sécurité virale transfusionnelle : le dépistage génomique viral

Assal, Azzedine; Coste, J.; Barlet, Valérie; Laperche, Syria; Cornillot, Cécile; Smilovici, W.; Pillonel, Josiane; Andreu, G.

doi:10.1016/s1246-7820(03)00049-1

Cited by 26 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study period, all blood donations were screened for HIV Abs, HBsAg, HBc Abs and HCV Abs with PRISM assays (Abbott Diagnostics, Rungis, France) in mainland France and ARCHITECT assays (Abbott) in the overseas territories (French West Indies, Reunion Island). HIV-1 and HCV-NAT screening was introduced in 2001 and performed in continental France in pool format by using either Chiron Procleix TMA HIV-1/HCV (Chiron, Emeryville, USA) in pools of 8 or Roche Cobas Ampliscreen HIV-1 and HCV (Roche Diagnostic, Meylan, France) in pools of 24, while it was performed in individual donation (ID) sample testing with Chiron assay in the overseas territories [6]. As of 2010, blood donations have been tested for viral genomes in ID testing with Procleix Ultrio assays (Grifols, Barcelona, Spain), including HBV-DNA testing.…”

Section: Blood Donation Testingmentioning

confidence: 99%

Human immunodeficiency virus, hepatitis C virus and hepatitis B virus incidence in blood donors from 2000 to 2020 in France: Trends and lessons from haemovigilance surveillance

Laperche,

Sauvage,

Gallian

et al. 2023

Vox Sanguinis

View full text Add to dashboard Cite

Background and ObjectivesData from 21 years (2000–2020) of haemovigilance were used to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence rates in repeat blood donors and the occurrence of transfusion‐transmitted (TT) viral infections.Materials and MethodsBlood donors who converted for HIV, HCV or HBV markers within serial three‐year analysis periods were included. Epidemiological and virological data were retrieved from the national epidemiological donor database and were supplemented with information on blood components and the infection status of recipients of the previous negative donation (D.N‐1) of donors who seroconverted.ResultsIncidence rates declined from 1.27 to 0.35/100,000 person‐years for HIV, from 0.59 to 0.19 for HCV and from 1.66 to 0.18 for HBV. Risk factors and lookback for 232 HIV, 90 HCV and 74 HBV seroconversions were investigated. The main risk factor identified at post‐donation interview was having sex with men (47.8% of males) for HIV and a sexual risk for HCV (30.6%) and HBV (37.1%). The viral loads and sequences were retrospectively tested in 191 HIV, 74 HCV and 62 HBV D.N‐1 archived samples. Six (five HBV and one HIV‐1) were positive all low viral loads. Two recipients were infected by red blood cells from two HBV seroconverting donors before the introduction of HBV‐nucleic acid testing.ConclusionHIV, HCV and HBV incidence rates in blood donors declined over the two past decades in France. There is a very small risk of a blood component that tests negative entering the blood supply resulting in TT infections, especially after introduction of molecular assays in donor screening.

show abstract

Section: Blood Donation Testingmentioning

confidence: 99%

Human immunodeficiency virus, hepatitis C virus and hepatitis B virus incidence in blood donors from 2000 to 2020 in France: Trends and lessons from haemovigilance surveillance

Laperche,

Sauvage,

Gallian

et al. 2023

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…Le dépistage génomique viral (DGV) du VHC chez les donneurs de sang (mis en place en juillet 2001) a permis après un an de pratique de dépister un don séroné-gatif-ARN positif sur un total d'environ 2,5 millions de dons [2]. Il faut toutefois remarquer que le DGV ne s'adresse qu'à des sujets rigoureusement sélectionnés.…”

Section: Utilisation Du Test Comme Technique De Dépistageunclassified

Antigénémie du virus de l'hépatite C : quel intérêt pour le laboratoire de biologie clinique ?

Dubrous¹,

Terrier

Gardet³

et al. 2005

Immuno-analyse & Biologie Spécialisée

View full text Add to dashboard Cite

“…In France, two commercial offers -Procleix (Gen-Probe, Inc. USA) and NucliSens Extractor (bioMerieux, France) associated with Cobas Ampliscreen (Roche Diagnostics, Switzerland)-are used to screen donations for HIV and HCV infections. This allowed the reduction of residual risk from 1 in 400,000 to 1 in 2.5 millions for HIV and 1 in 760,000 to 1 in 5 millions for HCV (Assal et al, 2003). However, there is room from improvement as few contaminated blood units are still missed due to the lack of sensitivity induced by pooling strategies.…”

Section: Viral Safetymentioning

confidence: 99%

Molecular diagnostics in virology

Vernet

2004

Journal of Clinical Virology

View full text Add to dashboard Cite

Molecular biology has significantly improved diagnosis in the field of clinical virology. Virus discovery and rapid implementation of diagnostic tests for newly discovered viruses has strongly beneficiated from the development of molecular techniques. Viral load and antiviral resistance or subtyping assays are now part of the biological monitoring of patients chronically infected by human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and CMV. It will be important to add to this panel assays for other viruses of the herpesviridae family. Qualitative assays for the detection of blood-borne viruses have increased safety of blood donation and organ transplantation. Screening of other blood-borne viruses (parvovirus B19, HAV), multiplexing of detection and test automation to improve practicability and reduce costs will be the next steps. A major evolution in the near future will be the generalization of NAT for the diagnosis of viral etiology in patients, mostly with respiratory, CNS or gastro-intestinal diseases. Major technical improvements have been made to avoid obstacles that still limit this generalization, i.e. genetic variability of viruses, multiplex detection, contamination risk. Commercial offers already exist but menus must be extended to limit the validation and documentation work associated with home-brew assays. Real-time amplification has allowed the development of new NAT platforms but automation and integration of all steps of the reaction are still required to reduce hands-on-time, time-to-result and costs, and to increase throughput.

show abstract

Application de la biologie moléculaire à la sécurité virale transfusionnelle : le dépistage génomique viral

Cited by 26 publications

References 5 publications

Human immunodeficiency virus, hepatitis C virus and hepatitis B virus incidence in blood donors from 2000 to 2020 in France: Trends and lessons from haemovigilance surveillance

Human immunodeficiency virus, hepatitis C virus and hepatitis B virus incidence in blood donors from 2000 to 2020 in France: Trends and lessons from haemovigilance surveillance

Antigénémie du virus de l'hépatite C : quel intérêt pour le laboratoire de biologie clinique ?

Molecular diagnostics in virology

Contact Info

Product

Resources

About